BindingDB logo
myBDB logout
Compile Data Set for Download or QSAR

Found 505 hits with Last Name = 'biagetti' and Initial = 'm'   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kJ/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Beta-2 adrenergic receptor


(Homo sapiens (Human))
BDBM50595424
PNG
(CHEMBL5172865)
Show SMILES Cn1nc(cc1COc1cccc(c1)[C@@H](NC(=O)O[C@H]1CN2CCC1CC2)c1ccccc1)C(=O)OCCCCNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:42.47,wD:14.16,19.20,(.73,4.28,;.18,2.84,;-1.31,2.44,;-1.39,.91,;.04,.35,;1.01,1.55,;2.55,1.47,;3.25,.1,;4.79,.01,;5.49,-1.36,;7.02,-1.44,;7.86,-.15,;7.16,1.22,;5.63,1.3,;8,2.51,;9.54,2.43,;10.24,1.06,;9.4,-.23,;11.78,.98,;12.48,-.4,;11.64,-1.69,;12.33,-3.06,;12.41,-1.64,;13.94,-1.9,;14.01,-.48,;14.71,-1.85,;13.87,-3.14,;7.31,3.89,;5.77,3.97,;5.07,5.34,;5.91,6.63,;7.45,6.55,;8.15,5.18,;-2.69,.07,;-2.61,-1.47,;-4.06,.77,;-5.35,-.07,;-6.72,.63,;-8.01,-.2,;-9.38,.5,;-10.68,-.34,;-12.05,.36,;-13.34,-.48,;-14.71,.22,;-13.26,-2.02,;-14.55,-2.86,;-14.47,-4.39,;-13.1,-5.09,;-13.02,-6.63,;-11.81,-4.26,;-10.44,-4.96,;-9.15,-4.12,;-7.77,-4.82,;-9.23,-2.58,;-10.6,-1.88,;-11.89,-2.72,)|
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
Purchase

MCE
PC cid
PC sid
UniChem
Article
PubMed
0.00398n/an/an/an/an/an/an/an/a



University of Maryland

Curated by ChEMBL




J Med Chem 48: 4500-3 (2005)


Article DOI: 10.1021/acs.jmedchem.2c00609
BindingDB Entry DOI: 10.7270/Q2TH8RQS
More data for this
Ligand-Target Pair
Beta-2 adrenergic receptor


(Homo sapiens (Human))
BDBM50595404
PNG
(CHEMBL5184455)
Show SMILES O[C@@H](CNCCCCOC(=O)c1ccc(COc2cccc(c2)[C@@H](NC(=O)O[C@H]2CN3CCC2CC3)c2ccccc2)cc1)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:1.0,wD:23.24,28.28,(-14.67,-1.16,;-13.33,-1.93,;-12,-1.16,;-10.67,-1.93,;-9.33,-1.16,;-8,-1.93,;-6.66,-1.16,;-5.33,-1.93,;-4,-1.16,;-2.66,-1.93,;-2.66,-3.47,;-1.33,-1.16,;.01,-1.93,;1.34,-1.16,;1.34,.38,;2.67,1.15,;4.01,.38,;5.34,1.15,;6.67,.39,;8,1.16,;8,2.69,;6.67,3.46,;5.34,2.69,;6.67,5,;8.01,5.77,;9.34,5,;9.34,3.46,;10.67,5.77,;12.01,5,;12.01,3.46,;13.34,2.69,;12.63,3.93,;14.05,4.54,;13.34,5.77,;14.67,5,;14.67,3.46,;5.34,5.77,;5.34,7.31,;4,8.08,;2.67,7.31,;2.67,5.77,;4,5,;-0,1.15,;-1.33,.38,;-13.33,-3.47,;-14.67,-4.24,;-14.67,-5.78,;-13.34,-6.54,;-13.34,-8.08,;-12,-5.77,;-10.67,-6.55,;-9.34,-5.77,;-8.01,-6.54,;-9.34,-4.24,;-10.67,-3.47,;-12,-4.24,)|
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
Article
PubMed
0.0200n/an/an/an/an/an/an/an/a



University of Maryland

Curated by ChEMBL




J Med Chem 48: 4500-3 (2005)


Article DOI: 10.1021/acs.jmedchem.2c00609
BindingDB Entry DOI: 10.7270/Q2TH8RQS
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417035
PNG
(CHEMBL1257993)
Show SMILES Fc1ccccc1-c1cnc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3ccccn3)CC2)cn1 |r,wU:13.13,wD:16.22,(15.52,-7.53,;14.76,-6.18,;13.23,-6.17,;12.47,-4.82,;13.26,-3.49,;14.8,-3.52,;15.55,-4.86,;17.09,-4.88,;17.88,-3.56,;19.42,-3.58,;20.17,-4.93,;21.71,-4.96,;22.45,-6.3,;23.99,-6.33,;24.79,-5.01,;26.33,-5.03,;27.07,-6.38,;28.2,-5.34,;29.54,-6.12,;29.22,-7.62,;30.25,-8.77,;27.69,-7.78,;30.95,-5.5,;32.19,-6.4,;33.6,-5.78,;33.76,-4.25,;32.51,-3.34,;31.11,-3.97,;26.27,-7.7,;24.74,-7.67,;19.38,-6.25,;17.85,-6.23,)|
Show InChI InChI=1S/C24H24FN5O2/c25-19-6-2-1-5-18(19)20-14-29-21(15-27-20)28-13-17-8-10-24(11-9-17)16-30(23(31)32-24)22-7-3-4-12-26-22/h1-7,12,14-15,17H,8-11,13,16H2,(H,28,29)/t17-,24-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.0251n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Beta-2 adrenergic receptor


(Homo sapiens (Human))
BDBM50595426
PNG
(CHEMBL5193853)
Show SMILES O[C@@H](CNCCCCOC(=O)c1cccc(COc2cccc(c2)[C@@H](NC(=O)O[C@H]2CN3CCC2CC3)c2ccccc2)c1)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:1.0,wD:24.25,29.29,(-13.81,.82,;-12.39,.23,;-11.16,1.16,;-9.74,.56,;-8.52,1.49,;-7.1,.89,;-5.87,1.82,;-4.45,1.23,;-3.22,2.16,;-1.8,1.56,;-1.61,.03,;-.58,2.49,;-.77,4.02,;.46,4.95,;1.88,4.35,;2.07,2.82,;3.49,2.22,;3.68,.7,;5.1,.1,;5.29,-1.43,;6.71,-2.03,;7.94,-1.1,;7.75,.43,;6.33,1.03,;8.98,1.36,;10.4,.76,;10.59,-.76,;9.36,-1.69,;12.01,-1.36,;12.2,-2.89,;10.97,-3.82,;11.16,-5.35,;11.72,-4.04,;13.07,-4.8,;13.62,-3.49,;13.81,-5.02,;12.58,-5.95,;8.78,2.89,;7.36,3.49,;7.17,5.02,;8.4,5.95,;9.82,5.35,;10.01,3.82,;.84,1.89,;-12.39,-1.31,;-13.73,-2.09,;-13.72,-3.63,;-12.39,-4.39,;-12.39,-5.93,;-11.06,-3.62,;-9.72,-4.39,;-8.4,-3.62,;-7.06,-4.39,;-8.4,-2.09,;-9.73,-1.32,;-11.06,-2.08,)|
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
Article
PubMed
0.0251n/an/an/an/an/an/an/an/a



University of Maryland

Curated by ChEMBL




J Med Chem 48: 4500-3 (2005)


Article DOI: 10.1021/acs.jmedchem.2c00609
BindingDB Entry DOI: 10.7270/Q2TH8RQS
More data for this
Ligand-Target Pair
Beta-2 adrenergic receptor


(Homo sapiens (Human))
BDBM50595427
PNG
(CHEMBL5200887)
Show SMILES COc1cc(ccc1COc1cccc(c1)[C@@H](NC(=O)O[C@H]1CN2CCC1CC2)c1ccccc1)C(=O)OCCCCNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:44.49,wD:16.18,21.22,(3.34,-1.15,;3.34,.39,;2,1.16,;.67,.39,;-.67,1.15,;-.67,2.69,;.67,3.47,;2,2.7,;3.33,3.47,;4.67,2.7,;6,3.47,;6,5.01,;7.33,5.78,;8.67,5.02,;8.67,3.48,;7.33,2.7,;10,2.71,;10,1.17,;8.67,.4,;7.34,1.16,;8.67,-1.14,;7.34,-1.92,;6.01,-1.15,;4.67,-1.92,;6.1,-1.92,;5.92,-3.46,;7.34,-3.46,;6.01,-4.23,;4.68,-3.46,;11.33,3.48,;11.33,5.02,;12.67,5.79,;14,5.02,;14,3.48,;12.67,2.71,;-2,.38,;-2,-1.16,;-3.33,1.15,;-4.67,.38,;-6,1.15,;-7.33,.38,;-8.67,1.14,;-10,.37,;-11.33,1.14,;-12.67,.37,;-14,1.14,;-12.67,-1.17,;-14,-1.94,;-14,-3.48,;-12.66,-4.25,;-12.66,-5.79,;-11.33,-3.48,;-9.99,-4.25,;-8.66,-3.48,;-7.33,-4.24,;-8.66,-1.94,;-10,-1.17,;-11.33,-1.94,)|
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
Article
PubMed
0.0251n/an/an/an/an/an/an/an/a



University of Maryland

Curated by ChEMBL




J Med Chem 48: 4500-3 (2005)


Article DOI: 10.1021/acs.jmedchem.2c00609
BindingDB Entry DOI: 10.7270/Q2TH8RQS
More data for this
Ligand-Target Pair
Beta-2 adrenergic receptor


(Homo sapiens (Human))
BDBM50595423
PNG
(CHEMBL5190387)
Show SMILES O[C@@H](CNCCCCOC(=O)c1ccc(COc2cccc(c2)[C@@H](NC(=O)O[C@H]2CN3CCC2CC3)c2ccccc2)o1)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:1.0,wD:23.24,28.28,(-14.71,.22,;-13.34,-.48,;-12.05,.36,;-10.68,-.34,;-9.38,.5,;-8.01,-.2,;-6.72,.63,;-5.35,-.07,;-4.06,.77,;-2.69,.07,;-2.61,-1.47,;-1.39,.91,;-1.31,2.44,;.18,2.84,;1.01,1.55,;2.55,1.47,;3.25,.1,;4.79,.01,;5.49,-1.36,;7.02,-1.44,;7.86,-.15,;7.16,1.22,;5.63,1.3,;8,2.51,;9.54,2.43,;10.24,1.06,;9.4,-.23,;11.78,.98,;12.48,-.4,;11.64,-1.69,;12.33,-3.06,;12.41,-1.64,;13.94,-1.9,;14.01,-.48,;14.71,-1.85,;13.87,-3.14,;7.31,3.89,;5.77,3.97,;5.07,5.34,;5.91,6.63,;7.45,6.55,;8.15,5.18,;.04,.35,;-13.26,-2.02,;-14.55,-2.86,;-14.47,-4.39,;-13.1,-5.09,;-13.02,-6.63,;-11.81,-4.26,;-10.44,-4.96,;-9.15,-4.12,;-7.77,-4.82,;-9.23,-2.58,;-10.6,-1.88,;-11.89,-2.72,)|
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
Article
PubMed
0.0251n/an/an/an/an/an/an/an/a



University of Maryland

Curated by ChEMBL




J Med Chem 48: 4500-3 (2005)


Article DOI: 10.1021/acs.jmedchem.2c00609
BindingDB Entry DOI: 10.7270/Q2TH8RQS
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417033
PNG
(CHEMBL1258111)
Show SMILES Fc1ccccc1-n1ccc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3ccccn3)CC2)n1 |r,wU:13.13,wD:16.22,(15.91,-.57,;14.51,.08,;13.26,-.81,;11.85,-.16,;11.72,1.37,;12.98,2.26,;14.38,1.6,;15.63,2.49,;15.65,4.03,;17.12,4.48,;18.01,3.23,;19.55,3.2,;20.3,1.86,;21.84,1.83,;22.63,3.15,;24.17,3.13,;24.91,1.78,;26.05,2.82,;27.39,2.04,;27.06,.54,;28.09,-.61,;25.53,.38,;28.79,2.66,;30.04,1.75,;31.44,2.38,;31.61,3.91,;30.35,4.82,;28.95,4.19,;24.12,.46,;22.59,.49,;17.08,1.99,)|
Show InChI InChI=1S/C23H24FN5O2/c24-18-5-1-2-6-19(18)29-14-10-20(27-29)26-15-17-8-11-23(12-9-17)16-28(22(30)31-23)21-7-3-4-13-25-21/h1-7,10,13-14,17H,8-9,11-12,15-16H2,(H,26,27)/t17-,23-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.0316n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417056
PNG
(CHEMBL1258225)
Show SMILES Fc1ccccc1-n1cc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3cncnc3)CC2)cn1 |r,wU:12.12,wD:15.21,(-5.79,-9.02,;-7.19,-8.37,;-8.44,-9.26,;-9.85,-8.61,;-9.98,-7.07,;-8.73,-6.19,;-7.33,-6.84,;-6.08,-5.96,;-4.62,-6.46,;-3.69,-5.22,;-2.15,-5.25,;-1.4,-6.59,;.14,-6.62,;.94,-5.3,;2.48,-5.31,;3.21,-6.67,;4.35,-5.63,;5.69,-6.41,;5.37,-7.91,;6.4,-9.06,;3.84,-8.08,;7.1,-5.79,;8.34,-6.69,;9.75,-6.07,;9.91,-4.54,;8.66,-3.63,;7.26,-4.26,;2.42,-7.99,;.89,-7.96,;-4.58,-3.96,;-6.05,-4.42,)|
Show InChI InChI=1S/C22H23FN6O2/c23-19-3-1-2-4-20(19)29-13-17(10-27-29)26-9-16-5-7-22(8-6-16)14-28(21(30)31-22)18-11-24-15-25-12-18/h1-4,10-13,15-16,26H,5-9,14H2/t16-,22-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.0398n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Beta-2 adrenergic receptor


(Homo sapiens (Human))
BDBM50595403
PNG
(CHEMBL5208201)
Show SMILES O[C@@H](CNCCCCOC(=O)c1ccc(COc2cccc(c2)C(NC(=O)O[C@H]2CN3CCC2CC3)c2ccccc2)cc1)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:1.0,wD:28.28,(-14.67,-1.16,;-13.33,-1.93,;-12,-1.16,;-10.66,-1.93,;-9.33,-1.16,;-8,-1.93,;-6.66,-1.16,;-5.33,-1.93,;-3.99,-1.16,;-2.66,-1.93,;-2.66,-3.47,;-1.33,-1.16,;.01,-1.93,;1.34,-1.16,;1.34,.38,;2.67,1.15,;4.01,.38,;5.34,1.15,;6.67,.39,;8,1.16,;8,2.69,;6.67,3.46,;5.34,2.69,;6.67,5,;8,5.77,;9.34,5,;9.34,3.46,;10.67,5.77,;12.01,5,;12.01,3.46,;13.34,2.69,;14.67,3.46,;14.67,5,;13.34,5.77,;14.05,4.54,;12.63,3.93,;5.34,5.77,;5.34,7.31,;4,8.08,;2.67,7.31,;2.67,5.77,;4,5,;-0,1.15,;-1.33,.38,;-13.33,-3.47,;-14.67,-4.24,;-14.67,-5.78,;-13.33,-6.54,;-13.33,-8.08,;-12,-5.77,;-10.67,-6.54,;-9.34,-5.77,;-8.01,-6.54,;-9.34,-4.24,;-10.67,-3.47,;-12,-4.24,)|
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
Article
PubMed
0.0398n/an/an/an/an/an/an/an/a



University of Maryland

Curated by ChEMBL




J Med Chem 48: 4500-3 (2005)


Article DOI: 10.1021/acs.jmedchem.2c00609
BindingDB Entry DOI: 10.7270/Q2TH8RQS
More data for this
Ligand-Target Pair
Beta-2 adrenergic receptor


(Homo sapiens (Human))
BDBM50595405
PNG
(CHEMBL5184598)
Show SMILES O[C@@H](CNCCCCOC(=O)c1ccc(COc2cccc(c2)[C@H](NC(=O)O[C@H]2CN3CCC2CC3)c2ccccc2)cc1)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:1.0,23.24,wD:28.28,(-14.67,-1.16,;-13.33,-1.93,;-12,-1.16,;-10.67,-1.93,;-9.33,-1.16,;-8,-1.93,;-6.66,-1.16,;-5.33,-1.93,;-4,-1.16,;-2.66,-1.93,;-2.66,-3.47,;-1.33,-1.16,;.01,-1.93,;1.34,-1.16,;1.34,.38,;2.67,1.15,;4.01,.38,;5.34,1.15,;6.67,.39,;8,1.16,;8,2.69,;6.67,3.46,;5.34,2.69,;6.67,5,;8,5.77,;9.34,5,;9.34,3.46,;10.67,5.77,;12.01,5,;12.01,3.46,;13.34,2.69,;12.63,3.93,;14.05,4.54,;13.34,5.77,;14.67,5,;14.67,3.46,;5.34,5.77,;5.34,7.31,;4,8.08,;2.67,7.31,;2.67,5.77,;4,5,;-0,1.15,;-1.33,.38,;-13.33,-3.47,;-14.67,-4.24,;-14.67,-5.78,;-13.34,-6.54,;-13.34,-8.08,;-12,-5.77,;-10.67,-6.54,;-9.34,-5.77,;-8.01,-6.54,;-9.34,-4.24,;-10.67,-3.47,;-12,-4.24,)|
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
Article
PubMed
0.0501n/an/an/an/an/an/an/an/a



University of Maryland

Curated by ChEMBL




J Med Chem 48: 4500-3 (2005)


Article DOI: 10.1021/acs.jmedchem.2c00609
BindingDB Entry DOI: 10.7270/Q2TH8RQS
More data for this
Ligand-Target Pair
Beta-2 adrenergic receptor


(Homo sapiens (Human))
BDBM50595425
PNG
(CHEMBL5208957)
Show SMILES O[C@@H](CNCCCCOC(=O)c1coc(COc2cccc(c2)[C@@H](NC(=O)O[C@H]2CN3CCC2CC3)c2ccccc2)n1)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:1.0,wD:23.24,28.28,(-14.71,.22,;-13.34,-.48,;-12.05,.36,;-10.68,-.34,;-9.38,.5,;-8.01,-.2,;-6.72,.63,;-5.35,-.07,;-4.06,.77,;-2.69,.07,;-2.61,-1.47,;-1.39,.91,;-1.31,2.44,;.18,2.84,;1.01,1.55,;2.55,1.47,;3.25,.1,;4.79,.01,;5.49,-1.36,;7.02,-1.44,;7.86,-.15,;7.16,1.22,;5.63,1.3,;8,2.51,;9.54,2.43,;10.24,1.06,;9.4,-.23,;11.78,.98,;12.48,-.4,;11.64,-1.69,;12.33,-3.06,;12.41,-1.64,;13.94,-1.9,;14.01,-.48,;14.71,-1.85,;13.87,-3.14,;7.31,3.89,;5.77,3.97,;5.07,5.34,;5.91,6.63,;7.45,6.55,;8.15,5.18,;.04,.35,;-13.26,-2.02,;-14.55,-2.86,;-14.47,-4.39,;-13.1,-5.09,;-13.02,-6.63,;-11.81,-4.26,;-10.44,-4.96,;-9.15,-4.12,;-7.77,-4.82,;-9.23,-2.58,;-10.6,-1.88,;-11.89,-2.72,)|
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
Article
PubMed
0.0501n/an/an/an/an/an/an/an/a



University of Maryland

Curated by ChEMBL




J Med Chem 48: 4500-3 (2005)


Article DOI: 10.1021/acs.jmedchem.2c00609
BindingDB Entry DOI: 10.7270/Q2TH8RQS
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM50595423
PNG
(CHEMBL5190387)
Show SMILES O[C@@H](CNCCCCOC(=O)c1ccc(COc2cccc(c2)[C@@H](NC(=O)O[C@H]2CN3CCC2CC3)c2ccccc2)o1)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:1.0,wD:23.24,28.28,(-14.71,.22,;-13.34,-.48,;-12.05,.36,;-10.68,-.34,;-9.38,.5,;-8.01,-.2,;-6.72,.63,;-5.35,-.07,;-4.06,.77,;-2.69,.07,;-2.61,-1.47,;-1.39,.91,;-1.31,2.44,;.18,2.84,;1.01,1.55,;2.55,1.47,;3.25,.1,;4.79,.01,;5.49,-1.36,;7.02,-1.44,;7.86,-.15,;7.16,1.22,;5.63,1.3,;8,2.51,;9.54,2.43,;10.24,1.06,;9.4,-.23,;11.78,.98,;12.48,-.4,;11.64,-1.69,;12.33,-3.06,;12.41,-1.64,;13.94,-1.9,;14.01,-.48,;14.71,-1.85,;13.87,-3.14,;7.31,3.89,;5.77,3.97,;5.07,5.34,;5.91,6.63,;7.45,6.55,;8.15,5.18,;.04,.35,;-13.26,-2.02,;-14.55,-2.86,;-14.47,-4.39,;-13.1,-5.09,;-13.02,-6.63,;-11.81,-4.26,;-10.44,-4.96,;-9.15,-4.12,;-7.77,-4.82,;-9.23,-2.58,;-10.6,-1.88,;-11.89,-2.72,)|
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
Article
PubMed
0.0631n/an/an/an/an/an/an/an/a



University of Maryland

Curated by ChEMBL




J Med Chem 48: 4500-3 (2005)


Article DOI: 10.1021/acs.jmedchem.2c00609
BindingDB Entry DOI: 10.7270/Q2TH8RQS
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM50595424
PNG
(CHEMBL5172865)
Show SMILES Cn1nc(cc1COc1cccc(c1)[C@@H](NC(=O)O[C@H]1CN2CCC1CC2)c1ccccc1)C(=O)OCCCCNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:42.47,wD:14.16,19.20,(.73,4.28,;.18,2.84,;-1.31,2.44,;-1.39,.91,;.04,.35,;1.01,1.55,;2.55,1.47,;3.25,.1,;4.79,.01,;5.49,-1.36,;7.02,-1.44,;7.86,-.15,;7.16,1.22,;5.63,1.3,;8,2.51,;9.54,2.43,;10.24,1.06,;9.4,-.23,;11.78,.98,;12.48,-.4,;11.64,-1.69,;12.33,-3.06,;12.41,-1.64,;13.94,-1.9,;14.01,-.48,;14.71,-1.85,;13.87,-3.14,;7.31,3.89,;5.77,3.97,;5.07,5.34,;5.91,6.63,;7.45,6.55,;8.15,5.18,;-2.69,.07,;-2.61,-1.47,;-4.06,.77,;-5.35,-.07,;-6.72,.63,;-8.01,-.2,;-9.38,.5,;-10.68,-.34,;-12.05,.36,;-13.34,-.48,;-14.71,.22,;-13.26,-2.02,;-14.55,-2.86,;-14.47,-4.39,;-13.1,-5.09,;-13.02,-6.63,;-11.81,-4.26,;-10.44,-4.96,;-9.15,-4.12,;-7.77,-4.82,;-9.23,-2.58,;-10.6,-1.88,;-11.89,-2.72,)|
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
Purchase

MCE
PC cid
PC sid
UniChem
Article
PubMed
0.0631n/an/an/an/an/an/an/an/a



University of Maryland

Curated by ChEMBL




J Med Chem 48: 4500-3 (2005)


Article DOI: 10.1021/acs.jmedchem.2c00609
BindingDB Entry DOI: 10.7270/Q2TH8RQS
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417051
PNG
(CHEMBL1258787)
Show SMILES Cc1ccccc1-c1ccc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3cccnn3)CC2)nn1 |r,wU:13.13,wD:16.22,(17.45,-6.84,;16.7,-5.5,;15.16,-5.48,;14.41,-4.13,;15.2,-2.81,;16.74,-2.83,;17.48,-4.18,;19.03,-4.2,;19.78,-5.55,;21.32,-5.57,;22.1,-4.25,;23.64,-4.27,;24.39,-5.62,;25.93,-5.64,;26.72,-4.32,;28.26,-4.34,;29,-5.69,;30.14,-4.66,;31.48,-5.43,;31.16,-6.94,;32.19,-8.08,;29.62,-7.1,;32.88,-4.81,;34.13,-5.72,;35.54,-5.1,;35.7,-3.56,;34.44,-2.66,;33.04,-3.29,;28.21,-7.01,;26.68,-6.98,;21.36,-2.9,;19.82,-2.87,)|
Show InChI InChI=1S/C24H26N6O2/c1-17-5-2-3-6-19(17)20-8-9-21(28-27-20)25-15-18-10-12-24(13-11-18)16-30(23(31)32-24)22-7-4-14-26-29-22/h2-9,14,18H,10-13,15-16H2,1H3,(H,25,28)/t18-,24-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.0631n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417036
PNG
(CHEMBL1257992)
Show SMILES Fc1ccccc1-c1ccc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3ccccn3)CC2)nn1 |r,wU:13.13,wD:16.22,(-7.93,-14.34,;-8.69,-13,;-10.22,-12.98,;-10.98,-11.63,;-10.19,-10.31,;-8.65,-10.33,;-7.9,-11.68,;-6.36,-11.69,;-5.6,-13.04,;-4.07,-13.06,;-3.28,-11.75,;-1.74,-11.77,;-1,-13.12,;.54,-13.14,;1.34,-11.82,;2.88,-11.84,;3.62,-13.19,;4.75,-12.16,;6.09,-12.93,;5.77,-14.44,;6.8,-15.58,;4.24,-14.6,;7.5,-12.31,;8.74,-13.22,;10.15,-12.59,;10.31,-11.06,;9.06,-10.15,;7.66,-10.78,;2.82,-14.51,;1.29,-14.48,;-4.03,-10.4,;-5.57,-10.37,)|
Show InChI InChI=1S/C24H24FN5O2/c25-19-6-2-1-5-18(19)20-8-9-21(29-28-20)27-15-17-10-12-24(13-11-17)16-30(23(31)32-24)22-7-3-4-14-26-22/h1-9,14,17H,10-13,15-16H2,(H,27,29)/t17-,24-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.0631n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417045
PNG
(CHEMBL1258341)
Show SMILES Fc1ccccc1-n1cc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3cnccn3)CC2)cn1 |r,wU:12.12,wD:15.21,(-6.54,-17.19,;-7.94,-16.54,;-9.19,-17.43,;-10.59,-16.78,;-10.73,-15.24,;-9.48,-14.36,;-8.08,-15.01,;-6.82,-14.13,;-5.37,-14.63,;-4.44,-13.39,;-2.9,-13.41,;-2.15,-14.76,;-.61,-14.79,;.19,-13.47,;1.73,-13.48,;2.46,-14.84,;3.6,-13.8,;4.94,-14.58,;4.62,-16.08,;5.64,-17.23,;3.09,-16.24,;6.35,-13.96,;7.58,-14.86,;8.99,-14.24,;9.15,-12.71,;7.91,-11.8,;6.5,-12.43,;1.67,-16.16,;.14,-16.13,;-5.33,-12.13,;-6.8,-12.59,)|
Show InChI InChI=1S/C22H23FN6O2/c23-18-3-1-2-4-19(18)29-14-17(12-27-29)26-11-16-5-7-22(8-6-16)15-28(21(30)31-22)20-13-24-9-10-25-20/h1-4,9-10,12-14,16,26H,5-8,11,15H2/t16-,22-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.0631n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417032
PNG
(CHEMBL1258110)
Show SMILES O=C1O[C@@]2(CN1c1ccccn1)CC[C@H](CNc1nc(cs1)-c1ccccn1)CC2 |r,wU:14.16,wD:3.2,(5.76,.15,;4.73,1.3,;3.2,1.14,;2.57,2.54,;3.71,3.58,;5.05,2.8,;6.45,3.43,;7.7,2.52,;9.11,3.14,;9.27,4.67,;8.02,5.58,;6.61,4.95,;1.83,3.89,;.29,3.91,;-.5,2.59,;-2.04,2.62,;-2.79,3.96,;-4.33,3.99,;-5.25,2.75,;-6.71,3.25,;-6.69,4.79,;-5.21,5.24,;-7.96,2.37,;-7.82,.84,;-9.08,-.05,;-10.48,.6,;-10.62,2.14,;-9.36,3.02,;.25,1.25,;1.78,1.22,)|
Show InChI InChI=1S/C22H23N5O2S/c28-21-27(19-6-2-4-12-24-19)15-22(29-21)9-7-16(8-10-22)13-25-20-26-18(14-30-20)17-5-1-3-11-23-17/h1-6,11-12,14,16H,7-10,13,15H2,(H,25,26)/t16-,22-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.0794n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM50595426
PNG
(CHEMBL5193853)
Show SMILES O[C@@H](CNCCCCOC(=O)c1cccc(COc2cccc(c2)[C@@H](NC(=O)O[C@H]2CN3CCC2CC3)c2ccccc2)c1)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:1.0,wD:24.25,29.29,(-13.81,.82,;-12.39,.23,;-11.16,1.16,;-9.74,.56,;-8.52,1.49,;-7.1,.89,;-5.87,1.82,;-4.45,1.23,;-3.22,2.16,;-1.8,1.56,;-1.61,.03,;-.58,2.49,;-.77,4.02,;.46,4.95,;1.88,4.35,;2.07,2.82,;3.49,2.22,;3.68,.7,;5.1,.1,;5.29,-1.43,;6.71,-2.03,;7.94,-1.1,;7.75,.43,;6.33,1.03,;8.98,1.36,;10.4,.76,;10.59,-.76,;9.36,-1.69,;12.01,-1.36,;12.2,-2.89,;10.97,-3.82,;11.16,-5.35,;11.72,-4.04,;13.07,-4.8,;13.62,-3.49,;13.81,-5.02,;12.58,-5.95,;8.78,2.89,;7.36,3.49,;7.17,5.02,;8.4,5.95,;9.82,5.35,;10.01,3.82,;.84,1.89,;-12.39,-1.31,;-13.73,-2.09,;-13.72,-3.63,;-12.39,-4.39,;-12.39,-5.93,;-11.06,-3.62,;-9.72,-4.39,;-8.4,-3.62,;-7.06,-4.39,;-8.4,-2.09,;-9.73,-1.32,;-11.06,-2.08,)|
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
Article
PubMed
0.0794n/an/an/an/an/an/an/an/a



University of Maryland

Curated by ChEMBL




J Med Chem 48: 4500-3 (2005)


Article DOI: 10.1021/acs.jmedchem.2c00609
BindingDB Entry DOI: 10.7270/Q2TH8RQS
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417042
PNG
(CHEMBL1257636)
Show SMILES Fc1ccccc1-n1cc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3cccnc3)CC2)cn1 |r,wU:12.12,wD:15.21,(-7.01,-.66,;-8.41,-.01,;-9.65,-.9,;-11.06,-.25,;-11.21,1.29,;-9.94,2.17,;-8.54,1.52,;-7.29,2.4,;-5.83,1.9,;-4.9,3.14,;-3.36,3.12,;-2.62,1.77,;-1.08,1.74,;-.28,3.07,;1.26,3.05,;2,1.7,;3.14,2.73,;4.48,1.96,;4.16,.45,;5.18,-.7,;2.62,.29,;5.88,2.57,;7.12,1.67,;8.53,2.29,;8.69,3.82,;7.44,4.73,;6.04,4.1,;1.21,.37,;-.33,.41,;-5.79,4.4,;-7.27,3.94,)|
Show InChI InChI=1S/C23H24FN5O2/c24-20-5-1-2-6-21(20)29-15-18(13-27-29)26-12-17-7-9-23(10-8-17)16-28(22(30)31-23)19-4-3-11-25-14-19/h1-6,11,13-15,17,26H,7-10,12,16H2/t17-,23-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.100n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417044
PNG
(CHEMBL1258340)
Show SMILES Fc1ccccc1-n1cc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3cccnc3F)CC2)cn1 |r,wU:12.12,wD:15.21,(17.14,-9.3,;15.74,-8.65,;14.5,-9.54,;13.09,-8.89,;12.95,-7.35,;14.21,-6.47,;15.61,-7.12,;16.86,-6.24,;18.32,-6.74,;19.25,-5.5,;20.79,-5.52,;21.54,-6.87,;23.08,-6.9,;23.87,-5.57,;25.41,-5.59,;26.15,-6.95,;27.29,-5.92,;28.63,-6.69,;28.31,-8.19,;29.34,-9.34,;26.78,-8.35,;30.04,-6.07,;31.28,-6.97,;32.69,-6.35,;32.85,-4.82,;31.6,-3.91,;30.2,-4.54,;28.95,-3.63,;25.36,-8.27,;23.83,-8.24,;18.36,-4.24,;16.89,-4.7,)|
Show InChI InChI=1S/C23H23F2N5O2/c24-18-4-1-2-5-19(18)30-14-17(13-28-30)27-12-16-7-9-23(10-8-16)15-29(22(31)32-23)20-6-3-11-26-21(20)25/h1-6,11,13-14,16,27H,7-10,12,15H2/t16-,23-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.100n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417046
PNG
(CHEMBL1258453)
Show SMILES Fc1ccccc1-n1cc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3cccnn3)CC2)cn1 |r,wU:12.12,wD:15.21,(16.1,-16.72,;14.7,-16.07,;13.45,-16.97,;12.04,-16.31,;11.91,-14.78,;13.16,-13.9,;14.56,-14.55,;15.81,-13.67,;17.27,-14.16,;18.2,-12.92,;19.74,-12.95,;20.49,-14.3,;22.03,-14.32,;22.82,-13,;24.36,-13.02,;25.1,-14.37,;26.24,-13.33,;27.58,-14.11,;27.26,-15.62,;28.28,-16.76,;25.73,-15.78,;28.99,-13.49,;30.23,-14.4,;31.63,-13.78,;31.8,-12.24,;30.55,-11.33,;29.15,-11.97,;24.31,-15.69,;22.78,-15.66,;17.31,-11.67,;15.84,-12.13,)|
Show InChI InChI=1S/C22H23FN6O2/c23-18-4-1-2-5-19(18)29-14-17(13-26-29)24-12-16-7-9-22(10-8-16)15-28(21(30)31-22)20-6-3-11-25-27-20/h1-6,11,13-14,16,24H,7-10,12,15H2/t16-,22-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.100n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417050
PNG
(CHEMBL1258674)
Show SMILES Fc1cc(F)cc(c1)-c1ccc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3cccnn3)CC2)nn1 |r,wU:14.14,wD:17.23,(-9.07,-1.62,;-8.32,-2.96,;-9.11,-4.29,;-8.36,-5.64,;-9.14,-6.96,;-6.82,-5.65,;-6.04,-4.34,;-6.78,-2.99,;-4.49,-4.35,;-3.74,-5.7,;-2.2,-5.72,;-1.42,-4.4,;.12,-4.43,;.87,-5.77,;2.41,-5.8,;3.2,-4.48,;4.74,-4.5,;5.48,-5.85,;6.62,-4.81,;7.96,-5.59,;7.64,-7.09,;8.67,-8.24,;6.1,-7.25,;9.36,-4.97,;10.61,-5.88,;12.02,-5.25,;12.18,-3.72,;10.92,-2.81,;9.52,-3.44,;4.69,-7.17,;3.16,-7.14,;-2.16,-3.06,;-3.7,-3.03,)|
Show InChI InChI=1S/C23H22F2N6O2/c24-17-10-16(11-18(25)12-17)19-3-4-20(29-28-19)26-13-15-5-7-23(8-6-15)14-31(22(32)33-23)21-2-1-9-27-30-21/h1-4,9-12,15H,5-8,13-14H2,(H,26,29)/t15-,23-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.100n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM50595404
PNG
(CHEMBL5184455)
Show SMILES O[C@@H](CNCCCCOC(=O)c1ccc(COc2cccc(c2)[C@@H](NC(=O)O[C@H]2CN3CCC2CC3)c2ccccc2)cc1)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:1.0,wD:23.24,28.28,(-14.67,-1.16,;-13.33,-1.93,;-12,-1.16,;-10.67,-1.93,;-9.33,-1.16,;-8,-1.93,;-6.66,-1.16,;-5.33,-1.93,;-4,-1.16,;-2.66,-1.93,;-2.66,-3.47,;-1.33,-1.16,;.01,-1.93,;1.34,-1.16,;1.34,.38,;2.67,1.15,;4.01,.38,;5.34,1.15,;6.67,.39,;8,1.16,;8,2.69,;6.67,3.46,;5.34,2.69,;6.67,5,;8.01,5.77,;9.34,5,;9.34,3.46,;10.67,5.77,;12.01,5,;12.01,3.46,;13.34,2.69,;12.63,3.93,;14.05,4.54,;13.34,5.77,;14.67,5,;14.67,3.46,;5.34,5.77,;5.34,7.31,;4,8.08,;2.67,7.31,;2.67,5.77,;4,5,;-0,1.15,;-1.33,.38,;-13.33,-3.47,;-14.67,-4.24,;-14.67,-5.78,;-13.34,-6.54,;-13.34,-8.08,;-12,-5.77,;-10.67,-6.55,;-9.34,-5.77,;-8.01,-6.54,;-9.34,-4.24,;-10.67,-3.47,;-12,-4.24,)|
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
Article
PubMed
0.126n/an/an/an/an/an/an/an/a



University of Maryland

Curated by ChEMBL




J Med Chem 48: 4500-3 (2005)


Article DOI: 10.1021/acs.jmedchem.2c00609
BindingDB Entry DOI: 10.7270/Q2TH8RQS
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM50569301
PNG
(CHEMBL4854091)
Show SMILES O[C@@H](CNCCc1ccc(COc2cccc(c2)[C@@H](NC(=O)O[C@H]2CN3CCC2CC3)c2ccccc2)cc1)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:1.0,18.19,wD:23.23,(1.74,-37.97,;3.08,-38.73,;4.41,-37.96,;5.75,-38.72,;7.08,-37.95,;8.41,-38.72,;9.75,-37.94,;11.08,-38.71,;12.41,-37.94,;12.4,-36.4,;13.74,-35.62,;15.07,-36.39,;16.4,-35.61,;16.39,-34.08,;17.71,-33.3,;19.06,-34.06,;19.06,-35.6,;17.73,-36.38,;20.4,-36.37,;21.73,-35.59,;23.07,-36.36,;23.07,-37.9,;24.4,-35.58,;25.74,-36.35,;25.73,-37.9,;27.06,-38.66,;28.39,-37.89,;28.39,-36.35,;27.05,-35.58,;27.81,-36.91,;26.28,-37.32,;20.41,-37.91,;19.08,-38.68,;19.08,-40.22,;20.42,-40.98,;21.76,-40.2,;21.74,-38.66,;11.06,-35.63,;9.73,-36.41,;3.08,-40.27,;1.76,-41.04,;1.75,-42.59,;3.09,-43.36,;3.09,-44.9,;4.42,-42.58,;5.75,-43.35,;7.09,-42.59,;8.42,-43.36,;7.09,-41.04,;5.75,-40.26,;4.42,-41.04,)|
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
Article
PubMed
0.126n/an/an/an/an/an/an/an/a



University of Maryland

Curated by ChEMBL




J Med Chem 48: 4500-3 (2005)


Article DOI: 10.1021/acs.jmedchem.2c00609
BindingDB Entry DOI: 10.7270/Q2TH8RQS
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417041
PNG
(CHEMBL1257637)
Show SMILES O=C1O[C@@]2(CN1c1ccccn1)CC[C@H](CNc1ccc(cn1)-c1nccs1)CC2 |r,wU:14.16,wD:3.2,(30.13,-31.33,;29.1,-30.19,;27.57,-30.35,;26.95,-28.94,;28.09,-27.91,;29.43,-28.68,;30.83,-28.06,;32.08,-28.97,;33.48,-28.34,;33.65,-26.81,;32.39,-25.9,;30.99,-26.53,;26.21,-27.59,;24.67,-27.57,;23.88,-28.89,;22.34,-28.87,;21.59,-27.52,;20.05,-27.5,;19.26,-28.81,;17.73,-28.79,;16.97,-27.44,;17.77,-26.12,;19.3,-26.15,;15.43,-27.43,;14.51,-28.66,;13.05,-28.17,;13.06,-26.63,;14.53,-26.17,;24.62,-30.23,;26.16,-30.26,)|
Show InChI InChI=1S/C22H23N5O2S/c28-21-27(19-3-1-2-10-23-19)15-22(29-21)8-6-16(7-9-22)13-25-18-5-4-17(14-26-18)20-24-11-12-30-20/h1-5,10-12,14,16H,6-9,13,15H2,(H,25,26)/t16-,22-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.126n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417390
PNG
(CHEMBL1289154)
Show SMILES FC(F)(F)Oc1ccc2nc([nH]c2c1)N1CCC2(CN(C(=O)O2)c2ccccc2)CC1
Show InChI InChI=1S/C21H19F3N4O3/c22-21(23,24)30-15-6-7-16-17(12-15)26-18(25-16)27-10-8-20(9-11-27)13-28(19(29)31-20)14-4-2-1-3-5-14/h1-7,12H,8-11,13H2,(H,25,26)
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.158n/an/an/an/an/an/an/an/a



GlaxoSmithKline

Curated by ChEMBL


Assay Description
Antagonistic activity at human NPY Y5 receptor expressed in HEK293 cells assessed as inhibition of calcium level by FLIPR assay


Bioorg Med Chem Lett 20: 7120-3 (2010)


Article DOI: 10.1016/j.bmcl.2010.09.064
BindingDB Entry DOI: 10.7270/Q2R49S2N
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417039
PNG
(CHEMBL1257761)
Show SMILES O=C1O[C@@]2(CN1c1ccccn1)CC[C@H](CNc1ccc(OC3CCC3)cn1)CC2 |r,wU:14.16,wD:3.2,(29.67,-25.14,;28.64,-23.99,;27.1,-24.16,;26.48,-22.75,;27.62,-21.72,;28.96,-22.49,;30.36,-21.87,;31.61,-22.78,;33.02,-22.15,;33.18,-20.62,;31.92,-19.71,;30.52,-20.34,;25.74,-21.4,;24.2,-21.38,;23.41,-22.7,;21.87,-22.68,;21.12,-21.33,;19.58,-21.3,;18.8,-22.62,;17.26,-22.6,;16.51,-21.25,;14.96,-21.24,;14.22,-19.89,;14.64,-18.41,;13.16,-17.99,;12.74,-19.47,;17.3,-19.93,;18.84,-19.96,;24.16,-24.04,;25.69,-24.07,)|
Show InChI InChI=1S/C23H28N4O3/c28-22-27(21-6-1-2-13-24-21)16-23(30-22)11-9-17(10-12-23)14-25-20-8-7-19(15-26-20)29-18-4-3-5-18/h1-2,6-8,13,15,17-18H,3-5,9-12,14,16H2,(H,25,26)/t17-,23-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.158n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417040
PNG
(CHEMBL1257760)
Show SMILES O=C1O[C@@]2(CN1c1ccccn1)CC[C@H](CNc1ccc(cn1)-c1ncccn1)CC2 |r,wU:14.16,wD:3.2,(7.1,-28.95,;6.07,-27.81,;4.54,-27.97,;3.92,-26.56,;5.06,-25.53,;6.4,-26.3,;7.8,-25.68,;9.05,-26.59,;10.45,-25.96,;10.62,-24.43,;9.36,-23.52,;7.96,-24.15,;3.18,-25.21,;1.64,-25.19,;.85,-26.51,;-.69,-26.49,;-1.44,-25.14,;-2.98,-25.12,;-3.77,-26.43,;-5.3,-26.41,;-6.06,-25.06,;-5.26,-23.74,;-3.73,-23.77,;-7.6,-25.05,;-8.35,-23.7,;-9.89,-23.68,;-10.68,-25,;-9.92,-26.35,;-8.38,-26.37,;1.59,-27.85,;3.13,-27.88,)|
Show InChI InChI=1S/C23H24N6O2/c30-22-29(20-4-1-2-11-24-20)16-23(31-22)9-7-17(8-10-23)14-27-19-6-5-18(15-28-19)21-25-12-3-13-26-21/h1-6,11-13,15,17H,7-10,14,16H2,(H,27,28)/t17-,23-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.158n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417054
PNG
(CHEMBL1258673)
Show SMILES Fc1ccccc1-c1ccc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3cccnn3)CC2)nn1 |r,wU:13.13,wD:16.22,(14.72,.44,;13.96,1.78,;12.43,1.8,;11.67,3.15,;12.46,4.47,;14,4.45,;14.75,3.1,;16.29,3.08,;17.04,1.73,;18.58,1.71,;19.36,3.03,;20.9,3.01,;21.65,1.66,;23.19,1.64,;23.99,2.96,;25.53,2.94,;26.26,1.59,;27.4,2.62,;28.74,1.85,;28.42,.34,;29.45,-.8,;26.89,.18,;30.15,2.47,;31.39,1.56,;32.8,2.18,;32.96,3.72,;31.71,4.62,;30.31,3.99,;25.47,.27,;23.94,.3,;18.62,4.38,;17.08,4.41,)|
Show InChI InChI=1S/C23H23FN6O2/c24-18-5-2-1-4-17(18)19-7-8-20(28-27-19)25-14-16-9-11-23(12-10-16)15-30(22(31)32-23)21-6-3-13-26-29-21/h1-8,13,16H,9-12,14-15H2,(H,25,28)/t16-,23-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.158n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM50595425
PNG
(CHEMBL5208957)
Show SMILES O[C@@H](CNCCCCOC(=O)c1coc(COc2cccc(c2)[C@@H](NC(=O)O[C@H]2CN3CCC2CC3)c2ccccc2)n1)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:1.0,wD:23.24,28.28,(-14.71,.22,;-13.34,-.48,;-12.05,.36,;-10.68,-.34,;-9.38,.5,;-8.01,-.2,;-6.72,.63,;-5.35,-.07,;-4.06,.77,;-2.69,.07,;-2.61,-1.47,;-1.39,.91,;-1.31,2.44,;.18,2.84,;1.01,1.55,;2.55,1.47,;3.25,.1,;4.79,.01,;5.49,-1.36,;7.02,-1.44,;7.86,-.15,;7.16,1.22,;5.63,1.3,;8,2.51,;9.54,2.43,;10.24,1.06,;9.4,-.23,;11.78,.98,;12.48,-.4,;11.64,-1.69,;12.33,-3.06,;12.41,-1.64,;13.94,-1.9,;14.01,-.48,;14.71,-1.85,;13.87,-3.14,;7.31,3.89,;5.77,3.97,;5.07,5.34,;5.91,6.63,;7.45,6.55,;8.15,5.18,;.04,.35,;-13.26,-2.02,;-14.55,-2.86,;-14.47,-4.39,;-13.1,-5.09,;-13.02,-6.63,;-11.81,-4.26,;-10.44,-4.96,;-9.15,-4.12,;-7.77,-4.82,;-9.23,-2.58,;-10.6,-1.88,;-11.89,-2.72,)|
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
Article
PubMed
0.158n/an/an/an/an/an/an/an/a



University of Maryland

Curated by ChEMBL




J Med Chem 48: 4500-3 (2005)


Article DOI: 10.1021/acs.jmedchem.2c00609
BindingDB Entry DOI: 10.7270/Q2TH8RQS
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM50595427
PNG
(CHEMBL5200887)
Show SMILES COc1cc(ccc1COc1cccc(c1)[C@@H](NC(=O)O[C@H]1CN2CCC1CC2)c1ccccc1)C(=O)OCCCCNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:44.49,wD:16.18,21.22,(3.34,-1.15,;3.34,.39,;2,1.16,;.67,.39,;-.67,1.15,;-.67,2.69,;.67,3.47,;2,2.7,;3.33,3.47,;4.67,2.7,;6,3.47,;6,5.01,;7.33,5.78,;8.67,5.02,;8.67,3.48,;7.33,2.7,;10,2.71,;10,1.17,;8.67,.4,;7.34,1.16,;8.67,-1.14,;7.34,-1.92,;6.01,-1.15,;4.67,-1.92,;6.1,-1.92,;5.92,-3.46,;7.34,-3.46,;6.01,-4.23,;4.68,-3.46,;11.33,3.48,;11.33,5.02,;12.67,5.79,;14,5.02,;14,3.48,;12.67,2.71,;-2,.38,;-2,-1.16,;-3.33,1.15,;-4.67,.38,;-6,1.15,;-7.33,.38,;-8.67,1.14,;-10,.37,;-11.33,1.14,;-12.67,.37,;-14,1.14,;-12.67,-1.17,;-14,-1.94,;-14,-3.48,;-12.66,-4.25,;-12.66,-5.79,;-11.33,-3.48,;-9.99,-4.25,;-8.66,-3.48,;-7.33,-4.24,;-8.66,-1.94,;-10,-1.17,;-11.33,-1.94,)|
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
Article
PubMed
0.200n/an/an/an/an/an/an/an/a



University of Maryland

Curated by ChEMBL




J Med Chem 48: 4500-3 (2005)


Article DOI: 10.1021/acs.jmedchem.2c00609
BindingDB Entry DOI: 10.7270/Q2TH8RQS
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417407
PNG
(CHEMBL1289153)
Show SMILES Fc1ccc(cc1)-c1ccc2[nH]c(nc2c1)N1CCC2(CN(C(=O)O2)c2ccccc2)CC1
Show InChI InChI=1S/C26H23FN4O2/c27-20-9-6-18(7-10-20)19-8-11-22-23(16-19)29-24(28-22)30-14-12-26(13-15-30)17-31(25(32)33-26)21-4-2-1-3-5-21/h1-11,16H,12-15,17H2,(H,28,29)
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.200n/an/an/an/an/an/an/an/a



GlaxoSmithKline

Curated by ChEMBL


Assay Description
Antagonistic activity at human NPY Y5 receptor expressed in HEK293 cells assessed as inhibition of calcium level by FLIPR assay


Bioorg Med Chem Lett 20: 7120-3 (2010)


Article DOI: 10.1016/j.bmcl.2010.09.064
BindingDB Entry DOI: 10.7270/Q2R49S2N
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417048
PNG
(CHEMBL1258562)
Show SMILES Cc1nnc(s1)N1C[C@@]2(CC[C@H](CNc3cnn(c3)-c3ccccc3F)CC2)OC1=O |r,wU:11.12,wD:8.31,(32.21,-20.6,;30.68,-20.6,;29.77,-19.35,;28.3,-19.82,;28.3,-21.36,;29.77,-21.84,;26.9,-21.98,;25.57,-21.2,;24.42,-22.24,;23.69,-20.88,;22.15,-20.86,;21.35,-22.19,;19.81,-22.16,;19.07,-20.81,;17.53,-20.79,;16.64,-19.53,;15.17,-19.99,;15.14,-21.53,;16.6,-22.03,;13.89,-22.41,;12.49,-21.76,;11.24,-22.64,;11.37,-24.18,;12.78,-24.83,;14.02,-23.94,;15.42,-24.59,;22.1,-23.53,;23.64,-23.56,;25.05,-23.64,;26.58,-23.48,;27.61,-24.63,)|
Show InChI InChI=1S/C21H23FN6O2S/c1-14-25-26-19(31-14)27-13-21(30-20(27)29)8-6-15(7-9-21)10-23-16-11-24-28(12-16)18-5-3-2-4-17(18)22/h2-5,11-12,15,23H,6-10,13H2,1H3/t15-,21-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.200n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417047
PNG
(CHEMBL1258454)
Show SMILES Fc1ccccc1-n1cc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3ccnnc3)CC2)cn1 |r,wU:12.12,wD:15.21,(-7.1,-25.51,;-8.5,-24.86,;-9.75,-25.75,;-11.16,-25.1,;-11.3,-23.56,;-10.04,-22.68,;-8.64,-23.33,;-7.38,-22.45,;-5.93,-22.95,;-5,-21.71,;-3.45,-21.73,;-2.71,-23.08,;-1.17,-23.1,;-.37,-21.78,;1.17,-21.8,;1.9,-23.15,;3.04,-22.12,;4.38,-22.89,;4.06,-24.4,;5.09,-25.55,;2.53,-24.56,;5.79,-22.28,;7.03,-23.18,;8.44,-22.56,;8.6,-21.03,;7.35,-20.12,;5.95,-20.75,;1.11,-24.48,;-.42,-24.44,;-5.89,-20.45,;-7.36,-20.91,)|
Show InChI InChI=1S/C22H23FN6O2/c23-19-3-1-2-4-20(19)29-14-17(12-27-29)24-11-16-5-8-22(9-6-16)15-28(21(30)31-22)18-7-10-25-26-13-18/h1-4,7,10,12-14,16,24H,5-6,8-9,11,15H2/t16-,22-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.200n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417055
PNG
(CHEMBL1258788)
Show SMILES Cc1cccc(n1)-c1ccc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3cccnn3)CC2)nc1 |r,wU:13.13,wD:16.22,(-8.85,-9.35,;-8.11,-10.7,;-8.9,-12.02,;-8.14,-13.37,;-6.6,-13.38,;-5.82,-12.07,;-6.57,-10.72,;-4.28,-12.08,;-3.52,-13.43,;-1.98,-13.45,;-1.2,-12.13,;.34,-12.16,;1.09,-13.51,;2.63,-13.53,;3.42,-12.21,;4.96,-12.23,;5.7,-13.58,;6.84,-12.55,;8.18,-13.32,;7.85,-14.82,;8.88,-15.97,;6.32,-14.99,;9.58,-12.7,;10.83,-13.61,;12.23,-12.98,;12.4,-11.45,;11.14,-10.54,;9.74,-11.17,;4.91,-14.9,;3.37,-14.87,;-1.95,-10.79,;-3.48,-10.76,)|
Show InChI InChI=1S/C24H26N6O2/c1-17-4-2-5-20(28-17)19-7-8-21(26-15-19)25-14-18-9-11-24(12-10-18)16-30(23(31)32-24)22-6-3-13-27-29-22/h2-8,13,15,18H,9-12,14,16H2,1H3,(H,25,26)/t18-,24-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.251n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Beta-2 adrenergic receptor


(Homo sapiens (Human))
BDBM50569301
PNG
(CHEMBL4854091)
Show SMILES O[C@@H](CNCCc1ccc(COc2cccc(c2)[C@@H](NC(=O)O[C@H]2CN3CCC2CC3)c2ccccc2)cc1)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:1.0,18.19,wD:23.23,(1.74,-37.97,;3.08,-38.73,;4.41,-37.96,;5.75,-38.72,;7.08,-37.95,;8.41,-38.72,;9.75,-37.94,;11.08,-38.71,;12.41,-37.94,;12.4,-36.4,;13.74,-35.62,;15.07,-36.39,;16.4,-35.61,;16.39,-34.08,;17.71,-33.3,;19.06,-34.06,;19.06,-35.6,;17.73,-36.38,;20.4,-36.37,;21.73,-35.59,;23.07,-36.36,;23.07,-37.9,;24.4,-35.58,;25.74,-36.35,;25.73,-37.9,;27.06,-38.66,;28.39,-37.89,;28.39,-36.35,;27.05,-35.58,;27.81,-36.91,;26.28,-37.32,;20.41,-37.91,;19.08,-38.68,;19.08,-40.22,;20.42,-40.98,;21.76,-40.2,;21.74,-38.66,;11.06,-35.63,;9.73,-36.41,;3.08,-40.27,;1.76,-41.04,;1.75,-42.59,;3.09,-43.36,;3.09,-44.9,;4.42,-42.58,;5.75,-43.35,;7.09,-42.59,;8.42,-43.36,;7.09,-41.04,;5.75,-40.26,;4.42,-41.04,)|
PDB
MMDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
Article
PubMed
0.251n/an/an/an/an/an/an/an/a



University of Maryland

Curated by ChEMBL




J Med Chem 48: 4500-3 (2005)


Article DOI: 10.1021/acs.jmedchem.2c00609
BindingDB Entry DOI: 10.7270/Q2TH8RQS
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417034
PNG
(CHEMBL1258224)
Show SMILES Fc1ccccc1-c1cnc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3ccccn3)CC2)nc1 |r,wU:13.13,wD:16.22,(-7.82,-7.93,;-8.57,-6.59,;-10.11,-6.57,;-10.86,-5.22,;-10.07,-3.9,;-8.53,-3.92,;-7.79,-5.27,;-6.24,-5.29,;-5.45,-3.96,;-3.91,-3.99,;-3.17,-5.34,;-1.63,-5.36,;-.88,-6.71,;.66,-6.73,;1.45,-5.41,;2.99,-5.43,;3.73,-6.78,;4.87,-5.75,;6.21,-6.52,;5.89,-8.03,;6.92,-9.17,;4.35,-8.19,;7.61,-5.9,;8.86,-6.81,;10.27,-6.19,;10.43,-4.65,;9.17,-3.75,;7.77,-4.37,;2.94,-8.1,;1.41,-8.07,;-3.95,-6.65,;-5.49,-6.64,)|
Show InChI InChI=1S/C24H24FN5O2/c25-20-6-2-1-5-19(20)18-14-28-22(29-15-18)27-13-17-8-10-24(11-9-17)16-30(23(31)32-24)21-7-3-4-12-26-21/h1-7,12,14-15,17H,8-11,13,16H2,(H,27,28,29)/t17-,24-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
0.316n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417052
PNG
(CHEMBL1258907)
Show SMILES Fc1cccnc1-c1ccc(NC[C@H]2CC[C@@]3(CN(C(=O)O3)c3cccnn3)CC2)nc1 |r,wU:13.13,wD:16.22,(16.94,-15.12,;16.19,-13.77,;14.65,-13.76,;13.89,-12.41,;14.68,-11.08,;16.22,-11.11,;16.97,-12.46,;18.51,-12.47,;19.27,-13.82,;20.8,-13.84,;21.59,-12.52,;23.13,-12.55,;23.88,-13.89,;25.42,-13.92,;26.21,-12.6,;27.75,-12.62,;28.49,-13.97,;29.63,-12.93,;30.97,-13.71,;30.64,-15.21,;31.67,-16.36,;29.11,-15.37,;32.37,-13.09,;33.62,-14,;35.02,-13.37,;35.19,-11.84,;33.93,-10.93,;32.53,-11.56,;27.7,-15.29,;26.16,-15.26,;20.84,-11.18,;19.31,-11.15,)|
Show InChI InChI=1S/C23H23FN6O2/c24-18-3-1-11-25-21(18)17-5-6-19(27-14-17)26-13-16-7-9-23(10-8-16)15-30(22(31)32-23)20-4-2-12-28-29-20/h1-6,11-12,14,16H,7-10,13,15H2,(H,26,27)/t16-,23-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.316n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417406
PNG
(CHEMBL1290037)
Show SMILES O=C1O[C@@]2(CN1c1ccccc1)CC[C@@H](CC2)c1nc2ccc(cc2[nH]1)C#N |r,wU:3.2,wD:14.19,(44.12,-48.11,;42.99,-47.06,;41.48,-47.37,;40.72,-46.03,;41.77,-44.89,;43.17,-45.54,;44.5,-44.78,;45.83,-45.57,;47.17,-44.82,;47.18,-43.28,;45.85,-42.49,;44.51,-43.25,;39.98,-47.38,;38.45,-47.41,;37.65,-46.09,;38.38,-44.74,;39.92,-44.71,;36.11,-46.12,;35.23,-47.4,;33.75,-46.95,;32.43,-47.76,;31.08,-47.02,;31.05,-45.47,;32.36,-44.67,;33.71,-45.4,;35.17,-44.89,;29.7,-44.74,;28.35,-43.96,)|
Show InChI InChI=1S/C22H20N4O2/c23-13-15-6-7-18-19(12-15)25-20(24-18)16-8-10-22(11-9-16)14-26(21(27)28-22)17-4-2-1-3-5-17/h1-7,12,16H,8-11,14H2,(H,24,25)/t16-,22-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.316n/an/an/an/an/an/an/an/a



GlaxoSmithKline

Curated by ChEMBL


Assay Description
Antagonistic activity at human NPY Y5 receptor expressed in HEK293 cells assessed as inhibition of calcium level by FLIPR assay


Bioorg Med Chem Lett 20: 7120-3 (2010)


Article DOI: 10.1016/j.bmcl.2010.09.064
BindingDB Entry DOI: 10.7270/Q2R49S2N
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417387
PNG
(CHEMBL1289386)
Show SMILES Fc1ccc(cc1)N1C[C@@]2(CC[C@@H](CC2)c2nc3ccc(OC(F)(F)F)cc3[nH]2)OC1=O |r,wU:9.32,wD:12.16,(48.29,-13.3,;46.95,-14.06,;46.93,-15.6,;45.59,-16.35,;44.26,-15.57,;44.28,-14.03,;45.61,-13.28,;42.93,-16.32,;41.53,-15.68,;40.48,-16.81,;39.74,-18.16,;38.21,-18.19,;37.41,-16.88,;38.14,-15.53,;39.68,-15.5,;35.87,-16.91,;34.99,-18.18,;33.51,-17.74,;32.19,-18.54,;30.84,-17.8,;30.81,-16.26,;29.46,-15.52,;29.42,-13.98,;28.07,-13.24,;30.74,-13.18,;29.46,-12.44,;32.12,-15.46,;33.47,-16.19,;34.93,-15.67,;41.24,-18.15,;42.75,-17.85,;43.88,-18.89,)|
Show InChI InChI=1S/C22H19F4N3O3/c23-14-1-3-15(4-2-14)29-12-21(32-20(29)30)9-7-13(8-10-21)19-27-17-6-5-16(11-18(17)28-19)31-22(24,25)26/h1-6,11,13H,7-10,12H2,(H,27,28)/t13-,21-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.316n/an/an/an/an/an/an/an/a



GlaxoSmithKline

Curated by ChEMBL


Assay Description
Antagonistic activity at human NPY Y5 receptor expressed in HEK293 cells assessed as inhibition of calcium level by FLIPR assay


Bioorg Med Chem Lett 20: 7120-3 (2010)


Article DOI: 10.1016/j.bmcl.2010.09.064
BindingDB Entry DOI: 10.7270/Q2R49S2N
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417405
PNG
(CHEMBL1289267)
Show SMILES FC(F)(F)Oc1ccc2nc([nH]c2c1)[C@H]1CC[C@@]2(CN(C(=O)O2)c2ccccc2)CC1 |r,wU:17.24,wD:14.15,(-14.1,-12.22,;-12.74,-12.96,;-11.43,-12.16,;-12.7,-11.42,;-12.72,-14.5,;-11.36,-15.24,;-11.32,-16.78,;-9.97,-17.52,;-8.66,-16.71,;-7.17,-17.16,;-6.29,-15.88,;-7.23,-14.65,;-8.69,-15.17,;-10.04,-14.44,;-4.76,-15.85,;-3.96,-17.17,;-2.43,-17.14,;-1.69,-15.79,;-.64,-14.66,;.76,-15.3,;.58,-16.83,;1.71,-17.87,;-.93,-17.13,;2.09,-14.55,;3.41,-15.33,;4.75,-14.58,;4.77,-13.04,;3.44,-12.26,;2.1,-13.01,;-2.48,-14.47,;-4.03,-14.5,)|
Show InChI InChI=1S/C22H20F3N3O3/c23-22(24,25)30-16-6-7-17-18(12-16)27-19(26-17)14-8-10-21(11-9-14)13-28(20(29)31-21)15-4-2-1-3-5-15/h1-7,12,14H,8-11,13H2,(H,26,27)/t14-,21-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.316n/an/an/an/an/an/an/an/a



GlaxoSmithKline

Curated by ChEMBL


Assay Description
Antagonistic activity at human NPY Y5 receptor expressed in HEK293 cells assessed as inhibition of calcium level by FLIPR assay


Bioorg Med Chem Lett 20: 7120-3 (2010)


Article DOI: 10.1016/j.bmcl.2010.09.064
BindingDB Entry DOI: 10.7270/Q2R49S2N
More data for this
Ligand-Target Pair
Muscarinic acetylcholine receptor M3


(Homo sapiens (Human))
BDBM50595403
PNG
(CHEMBL5208201)
Show SMILES O[C@@H](CNCCCCOC(=O)c1ccc(COc2cccc(c2)C(NC(=O)O[C@H]2CN3CCC2CC3)c2ccccc2)cc1)c1ccc(O)c2[nH]c(=O)ccc12 |r,wU:1.0,wD:28.28,(-14.67,-1.16,;-13.33,-1.93,;-12,-1.16,;-10.66,-1.93,;-9.33,-1.16,;-8,-1.93,;-6.66,-1.16,;-5.33,-1.93,;-3.99,-1.16,;-2.66,-1.93,;-2.66,-3.47,;-1.33,-1.16,;.01,-1.93,;1.34,-1.16,;1.34,.38,;2.67,1.15,;4.01,.38,;5.34,1.15,;6.67,.39,;8,1.16,;8,2.69,;6.67,3.46,;5.34,2.69,;6.67,5,;8,5.77,;9.34,5,;9.34,3.46,;10.67,5.77,;12.01,5,;12.01,3.46,;13.34,2.69,;14.67,3.46,;14.67,5,;13.34,5.77,;14.05,4.54,;12.63,3.93,;5.34,5.77,;5.34,7.31,;4,8.08,;2.67,7.31,;2.67,5.77,;4,5,;-0,1.15,;-1.33,.38,;-13.33,-3.47,;-14.67,-4.24,;-14.67,-5.78,;-13.33,-6.54,;-13.33,-8.08,;-12,-5.77,;-10.67,-6.54,;-9.34,-5.77,;-8.01,-6.54,;-9.34,-4.24,;-10.67,-3.47,;-12,-4.24,)|
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
Article
PubMed
0.316n/an/an/an/an/an/an/an/a



University of Maryland

Curated by ChEMBL




J Med Chem 48: 4500-3 (2005)


Article DOI: 10.1021/acs.jmedchem.2c00609
BindingDB Entry DOI: 10.7270/Q2TH8RQS
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50416448
PNG
(CHEMBL1209159)
Show SMILES CC(C(=O)N1C[C@H]2[C@@H](CNc3nc(cs3)-c3ccccn3)[C@H]2C1)c1ccccc1 |r|
Show InChI InChI=1S/C23H24N4OS/c1-15(16-7-3-2-4-8-16)22(28)27-12-18-17(19(18)13-27)11-25-23-26-21(14-29-23)20-9-5-6-10-24-20/h2-10,14-15,17-19H,11-13H2,1H3,(H,25,26)/t15?,17-,18+,19-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.398n/an/an/an/an/an/an/an/a



GlaxoSmithKline

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor expressed in HEK293 cells assessed as inhibition of calcium level by FLIPR assay


Bioorg Med Chem Lett 20: 4741-4 (2010)


Article DOI: 10.1016/j.bmcl.2010.06.140
BindingDB Entry DOI: 10.7270/Q2JS9QMP
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417404
PNG
(CHEMBL1289609)
Show SMILES Cc1cccc(n1)N1C[C@@]2(CC[C@@H](CC2)c2nc3ccc(OC(F)(F)F)cc3[nH]2)OC1=O |r,wU:9.32,wD:12.16,(4.72,-25.12,;4.71,-26.66,;6.04,-27.44,;6.02,-28.99,;4.68,-29.74,;3.36,-28.95,;3.37,-27.42,;2.02,-29.7,;.63,-29.06,;-.42,-30.2,;-1.16,-31.54,;-2.7,-31.58,;-3.49,-30.26,;-2.76,-28.91,;-1.22,-28.88,;-5.03,-30.29,;-5.91,-31.56,;-7.39,-31.12,;-8.71,-31.92,;-10.06,-31.19,;-10.09,-29.64,;-11.46,-28.9,;-11.48,-27.37,;-12.84,-26.63,;-10.17,-26.56,;-11.44,-25.82,;-8.78,-28.84,;-7.43,-29.57,;-5.97,-29.06,;.34,-31.53,;1.85,-31.23,;2.98,-32.28,)|
Show InChI InChI=1S/C22H21F3N4O3/c1-13-3-2-4-18(26-13)29-12-21(32-20(29)30)9-7-14(8-10-21)19-27-16-6-5-15(11-17(16)28-19)31-22(23,24)25/h2-6,11,14H,7-10,12H2,1H3,(H,27,28)/t14-,21-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.398n/an/an/an/an/an/an/an/a



GlaxoSmithKline

Curated by ChEMBL


Assay Description
Antagonistic activity at human NPY Y5 receptor expressed in HEK293 cells assessed as inhibition of calcium level by FLIPR assay


Bioorg Med Chem Lett 20: 7120-3 (2010)


Article DOI: 10.1016/j.bmcl.2010.09.064
BindingDB Entry DOI: 10.7270/Q2R49S2N
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50416445
PNG
(CHEMBL1209162)
Show SMILES O=C(CCc1ccccc1)N1C[C@H]2[C@@H](CNc3nc(cs3)-c3ccccn3)[C@H]2C1 |r|
Show InChI InChI=1S/C23H24N4OS/c28-22(10-9-16-6-2-1-3-7-16)27-13-18-17(19(18)14-27)12-25-23-26-21(15-29-23)20-8-4-5-11-24-20/h1-8,11,15,17-19H,9-10,12-14H2,(H,25,26)/t17-,18+,19-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.631n/an/an/an/an/an/an/an/a



GlaxoSmithKline

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor expressed in HEK293 cells assessed as inhibition of calcium level by FLIPR assay


Bioorg Med Chem Lett 20: 4741-4 (2010)


Article DOI: 10.1016/j.bmcl.2010.06.140
BindingDB Entry DOI: 10.7270/Q2JS9QMP
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417402
PNG
(CHEMBL1289820)
Show SMILES FC(F)(F)c1ccc2nc([nH]c2c1)[C@H]1CC[C@@]2(CN(C(=O)O2)c2ccccc2)CC1 |r,wU:16.23,wD:13.14,(28.53,-36.29,;28.56,-37.83,;27.25,-38.63,;27.22,-37.06,;29.91,-38.57,;29.95,-40.11,;31.3,-40.85,;32.61,-40.05,;34.1,-40.49,;34.98,-39.22,;34.04,-37.99,;32.58,-38.5,;31.22,-37.77,;36.51,-39.19,;37.31,-40.51,;38.84,-40.47,;39.59,-39.12,;40.63,-37.99,;42.03,-38.63,;41.86,-40.16,;42.99,-41.2,;40.35,-40.46,;43.37,-37.88,;44.69,-38.67,;46.03,-37.91,;46.05,-36.37,;44.71,-35.59,;43.38,-36.35,;38.79,-37.81,;37.24,-37.84,)|
Show InChI InChI=1S/C22H20F3N3O2/c23-22(24,25)15-6-7-17-18(12-15)27-19(26-17)14-8-10-21(11-9-14)13-28(20(29)30-21)16-4-2-1-3-5-16/h1-7,12,14H,8-11,13H2,(H,26,27)/t14-,21-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.631n/an/an/an/an/an/an/an/a



GlaxoSmithKline

Curated by ChEMBL


Assay Description
Antagonistic activity at human NPY Y5 receptor expressed in HEK293 cells assessed as inhibition of calcium level by FLIPR assay


Bioorg Med Chem Lett 20: 7120-3 (2010)


Article DOI: 10.1016/j.bmcl.2010.09.064
BindingDB Entry DOI: 10.7270/Q2R49S2N
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50416460
PNG
(CHEMBL1209345)
Show SMILES Fc1cc(F)cc(CN2C[C@H]3[C@@H](CNc4nc(cs4)-c4ccccn4)[C@H]3C2)c1 |r|
Show InChI InChI=1S/C21H20F2N4S/c22-14-5-13(6-15(23)7-14)9-27-10-17-16(18(17)11-27)8-25-21-26-20(12-28-21)19-3-1-2-4-24-19/h1-7,12,16-18H,8-11H2,(H,25,26)/t16-,17+,18-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.631n/an/an/an/an/an/an/an/a



GlaxoSmithKline

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor expressed in HEK293 cells assessed as inhibition of calcium level by FLIPR assay


Bioorg Med Chem Lett 20: 4741-4 (2010)


Article DOI: 10.1016/j.bmcl.2010.06.140
BindingDB Entry DOI: 10.7270/Q2JS9QMP
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417043
PNG
(CHEMBL1257520)
Show SMILES Cc1ncccc1N1C[C@@]2(CC[C@H](CNc3cnn(c3)-c3ccccc3F)CC2)OC1=O |r,wU:12.13,wD:9.32,(27.95,3.78,;29.2,2.88,;30.61,3.51,;31.86,2.6,;31.69,1.07,;30.29,.45,;29.05,1.35,;27.64,.73,;26.3,1.5,;25.16,.47,;24.42,1.83,;22.88,1.84,;22.08,.52,;20.54,.55,;19.8,1.89,;18.26,1.92,;17.37,3.18,;15.89,2.72,;15.87,1.18,;17.33,.68,;14.61,.3,;13.22,.95,;11.96,.07,;12.1,-1.47,;13.5,-2.12,;14.75,-1.23,;16.15,-1.88,;22.84,-.82,;24.37,-.85,;25.79,-.94,;27.32,-.77,;28.34,-1.92,)|
Show InChI InChI=1S/C24H26FN5O2/c1-17-21(7-4-12-26-17)29-16-24(32-23(29)31)10-8-18(9-11-24)13-27-19-14-28-30(15-19)22-6-3-2-5-20(22)25/h2-7,12,14-15,18,27H,8-11,13,16H2,1H3/t18-,24-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.631n/an/an/an/an/an/an/an/a



GlaxoSmithKline SpA

Curated by ChEMBL


Assay Description
Antagonist activity at human NPY Y5 receptor


Bioorg Med Chem Lett 20: 6103-7 (2010)


Article DOI: 10.1016/j.bmcl.2010.08.041
BindingDB Entry DOI: 10.7270/Q2JM2BWB
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417386
PNG
(CHEMBL1289268)
Show SMILES Fc1ccccc1N1C[C@@]2(CC[C@@H](CC2)c2nc3ccc(OC(F)(F)F)cc3[nH]2)OC1=O |r,wU:9.32,wD:12.16,(21.81,-13.52,;23.13,-14.3,;24.47,-13.55,;25.8,-14.33,;25.78,-15.87,;24.44,-16.62,;23.12,-15.84,;21.78,-16.59,;20.39,-15.95,;19.34,-17.08,;18.6,-18.43,;17.06,-18.46,;16.27,-17.15,;17,-15.79,;18.54,-15.76,;14.73,-17.18,;13.85,-18.45,;12.37,-18.01,;11.05,-18.81,;9.7,-18.07,;9.67,-16.53,;8.32,-15.79,;8.28,-14.25,;6.93,-13.51,;9.59,-13.45,;8.32,-12.71,;10.98,-15.73,;12.33,-16.46,;13.79,-15.94,;20.1,-18.42,;21.61,-18.12,;22.74,-19.16,)|
Show InChI InChI=1S/C22H19F4N3O3/c23-15-3-1-2-4-18(15)29-12-21(32-20(29)30)9-7-13(8-10-21)19-27-16-6-5-14(11-17(16)28-19)31-22(24,25)26/h1-6,11,13H,7-10,12H2,(H,27,28)/t13-,21-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.631n/an/an/an/an/an/an/an/a



GlaxoSmithKline

Curated by ChEMBL


Assay Description
Antagonistic activity at human NPY Y5 receptor expressed in HEK293 cells assessed as inhibition of calcium level by FLIPR assay


Bioorg Med Chem Lett 20: 7120-3 (2010)


Article DOI: 10.1016/j.bmcl.2010.09.064
BindingDB Entry DOI: 10.7270/Q2R49S2N
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 5


(Homo sapiens (Human))
BDBM50417403
PNG
(CHEMBL1290038)
Show SMILES Fc1ccc(cc1)N1C[C@@]2(CC[C@@H](CC2)c2nc3ccc(cc3[nH]2)C#N)OC1=O |r,wU:9.29,wD:12.16,(8.45,-40.09,;7.11,-40.85,;7.09,-42.39,;5.75,-43.14,;4.42,-42.35,;4.44,-40.82,;5.77,-40.06,;3.09,-43.11,;1.69,-42.46,;.65,-43.6,;-.1,-44.95,;-1.63,-44.98,;-2.43,-43.66,;-1.7,-42.31,;-.15,-42.28,;-3.96,-43.69,;-4.85,-44.97,;-6.33,-44.52,;-7.64,-45.33,;-8.99,-44.59,;-9.03,-43.05,;-7.72,-42.24,;-6.37,-42.98,;-4.9,-42.46,;-10.38,-42.31,;-11.72,-41.54,;1.41,-44.94,;2.91,-44.64,;4.05,-45.68,)|
Show InChI InChI=1S/C22H19FN4O2/c23-16-2-4-17(5-3-16)27-13-22(29-21(27)28)9-7-15(8-10-22)20-25-18-6-1-14(12-24)11-19(18)26-20/h1-6,11,15H,7-10,13H2,(H,25,26)/t15-,22-
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
0.631n/an/an/an/an/an/an/an/a



GlaxoSmithKline

Curated by ChEMBL


Assay Description
Antagonistic activity at human NPY Y5 receptor expressed in HEK293 cells assessed as inhibition of calcium level by FLIPR assay


Bioorg Med Chem Lett 20: 7120-3 (2010)


Article DOI: 10.1016/j.bmcl.2010.09.064
BindingDB Entry DOI: 10.7270/Q2R49S2N
More data for this
Ligand-Target Pair
Displayed 1 to 50 (of 505 total )  |  Next  |  Last  >>
Jump to: